We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Transition Bio Stock

Invest in or calculate the value of your shares in Transition Bio or other pre-IPO companies through EquityZen's platform.

Get Started

Transition Bio Stock (TRNB)

Transition Bio provides condensate technology for drug discovery and diagnostics.

About Transition Bio Stock

Founded

2020

Headquarters

Cambridge, MA, US

Industries

Software, Artificial Intelligence, Financial Services

Transition Bio provides condensate technology for drug discovery and diagnostics. The company focuses on the discovery, analysis, and modulation of biological condensates, propelled by a differentiated technological capability that generates expansive drug development opportunities in a hypothesis-free manner.

Transition Bio Press Mentions

Stay in the know about the latest news on Transition Bio

High-throughput condensate modulator screen

patents • May 04, 2025

Kadi Liis Saar’s Post

linkedin • Aug 03, 2024

Transition Bio Closes $50M Series A Financing

vcnewsdaily • Jun 11, 2023

Transition Bio unveils $50 million Series A investment round

businessweekly • Jun 11, 2022

Transition Bio Closes $50M Series A Financing

finsmes • Jun 03, 2022

Transition Bio Management

Leadership team at Transition Bio

Chairman

Kelly Martin

Chief Operating Officer

Martin Kulander

Locked Features

Join now and verify your accreditation status to gain access to:

  • Transition Bio Current Valuation
  • Transition Bio Stock Price
  • Transition Bio Management
  • Available deals in Transition Bio and all other companies with relevant Deal Offering documents
  • EquityZen's proprietary data and insights, which may include
    • Transition Bio Cap Table and Funding History by Share Class and Liquidity Preferences
    • Transition Bio Revenue and Financials
    • Transition Bio Highlights
    • Transition Bio Business Model
    • Transition Bio Risk Factors
  • Transition Bio Research Report from SACRA Research
Join Now

Trading Transition Bio Stock

How to invest in Transition Bio stock?

Accredited investors can buy pre-IPO stock in companies like Transition Bio through EquityZen funds. These investments are made available by existing Transition Bio shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Transition Bio stock?

Shareholders can sell their Transition Bio stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."